blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3774790

EP3774790 - OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.12.2023
Database last updated on 14.06.2024
FormerThe patent has been granted
Status updated on  23.12.2022
FormerGrant of patent is intended
Status updated on  16.08.2022
FormerExamination is in progress
Status updated on  10.12.2021
FormerRequest for examination was made
Status updated on  15.01.2021
FormerThe international publication has been made
Status updated on  05.10.2019
Formerunknown
Status updated on  11.05.2019
Most recent event   Tooltip09.02.2024Lapse of the patent in a contracting state
New state(s): SI
published on 13.03.2024  [2024/11]
Applicant(s)For all designated states
Bugworks Research, Inc.
2711 Centerville Road, Suite 400
Wilmington, DE 19808 / US
[2021/07]
Inventor(s)01 / PEER MOHAMED, Shahul Hameed
Bugworks Research India Pvt. Ltd.
EVOMA, 88 Borewell Road
Whitefield, Bengaluru 560066 / IN
02 / BHARATHAM, Nagakumar
Bugworks Research India Pvt. Ltd.
EVOMA, 88 Borewell Road
Whitefield, Bengaluru 560066 / IN
03 / KATAGIHALLIMATH, Nainesh
Bugworks Research India Pvt. Ltd.
EVOMA, 88 Borewell Road
Whitefield, Bengaluru 560066 / IN
04 / SHARMA, Sreevalli
Bugworks Research India Pvt. Ltd.
EVOMA, 88 Borewell Road
Whitefield, Bengaluru 560066 / IN
05 / NANDISHAIAH, Radha
Bugworks Research India Pvt. Ltd.
EVOMA, 88 Borewell Road
Whitefield, Bengaluru 560066 / IN
06 / RAMACHANDRAN, Vasanthi
Bugworks Research India Pvt. Ltd.
EVOMA, 88 Borewell Road
Whitefield, Bengaluru 560066 / IN
 [2021/07]
Representative(s)Jones, Nicholas Andrew
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[2023/04]
Former [2021/07]Jones, Nicholas Andrew
Withers & Rogers LLP
4 More London Riverside
London, SE1 2AU / GB
Application number, filing date19721148.528.03.2019
[2021/07]
WO2019IN50252
Priority number, dateIN20184101176528.03.2018         Original published format: IN201841011765
[2021/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019186590
Date:03.10.2019
Language:EN
[2019/40]
Type: A1 Application with search report 
No.:EP3774790
Date:17.02.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 03.10.2019 takes the place of the publication of the European patent application.
[2021/07]
Type: B1 Patent specification 
No.:EP3774790
Date:25.01.2023
Language:EN
[2023/04]
Search report(s)International search report - published on:EP03.10.2019
ClassificationIPC:C07D413/14, C07D417/04, C07D417/14, C07D471/04, C07D498/04, A61K31/536, A61K31/4985, A61K31/5365, A61K31/5377, A61K31/5386, A61P31/00
[2021/07]
CPC:
C07D413/14 (EP); A61K31/542 (US); A61K31/4985 (EP);
A61K31/5365 (EP); A61K31/5377 (EP); A61K31/5383 (US);
A61K31/5386 (EP); A61P31/00 (EP); A61P31/04 (US);
C07D417/04 (EP); C07D417/14 (EP); C07D471/04 (EP);
C07D498/04 (EP); C07D519/00 (US); Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/07]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:ANTIBIOTISCHE OXAZOLIDINONVERBINDUNGEN UND VERFAHREN ZUR HERSTELLUNG[2021/07]
English:OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION[2021/07]
French:COMPOSÉS ANTIBIOTIQUES D'OXAZOLIDINONE ET PROCÉDÉS DE PRÉPARATION[2021/07]
Entry into regional phase19.10.2020National basic fee paid 
19.10.2020Designation fee(s) paid 
19.10.2020Examination fee paid 
Examination procedure19.10.2020Amendment by applicant (claims and/or description)
19.10.2020Examination requested  [2021/07]
19.10.2020Date on which the examining division has become responsible
13.12.2021Despatch of a communication from the examining division (Time limit: M04)
13.04.2022Reply to a communication from the examining division
10.05.2022Despatch of a communication from the examining division (Time limit: M02)
13.07.2022Reply to a communication from the examining division
17.08.2022Communication of intention to grant the patent
19.12.2022Fee for grant paid
19.12.2022Fee for publishing/printing paid
19.12.2022Receipt of the translation of the claim(s)
Opposition(s)26.10.2023No opposition filed within time limit [2024/01]
Fees paidRenewal fee
19.10.2020Renewal fee patent year 03
18.03.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipEE25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
SI25.01.2023
SK25.01.2023
LU28.03.2023
IS25.05.2023
[2024/11]
Former [2024/02]EE25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
SK25.01.2023
LU28.03.2023
IS25.05.2023
Former [2023/50]EE25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
SK25.01.2023
IS25.05.2023
Former [2023/48]EE25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
IS25.05.2023
Former [2023/39]LT25.01.2023
LV25.01.2023
IS25.05.2023
Former [2023/36]LT25.01.2023
LV25.01.2023
Former [2023/33]LT25.01.2023
Cited inInternational search[Y]WO2008126024  (ACTELION PHARMACEUTICALS LTD [CH], et al) [Y] 1-19 * page 1, lines 2-7; page 9, line 5 to page 11, line 19; page 21, line 25; page 23, lines 3-7; page 77, Scheme 1, "I-3 + I-2 -> I-a"; page 78, Scheme 2; pages 274-275, "Pharmacological properties of the invention compounds" *;
 [Y]WO2009104159  (ACTELION PHARMACEUTICALS LTD [CH], et al) [Y] 1-19 * page 2, line 6 to page 3, line 14; page 5, line 17 to page 6, line 1, e.g. group G5; page 18, line 28 to page 20, line 12; page 36, first reaction scheme (Ia) and (Ib); page 95, "Results" *;
 [Y]WO2013021363  (ACTELION PHARMACEUTICALS LTD [CH], et al) [Y] 1-19* page 1, lines 1-6; page 7, compound of formula I; pages 36-40, e.g. reaction of compound IX with compound X to prepare compound XI or compound XII; pages 108-110, "Pharmacological properties of the invention compounds" *;
 [Y]WO2017199265  (BUGWORKS RES INDIA PVT LTD [IN]) [Y] 1-19 * [0005]-[0006]; [00045]; [00058]; examples, e.g. Example 1, in particular the reaction scheme for preparing the compound of Example 1; pages 89-98, "Biological activity", e.g. Tables 1 to 3; claims, e.g. Claim 3 *
by applicantWO2017199265
 WO2018225097
    - CHEMICAL ABSTRACTS, Database accession no. 2156619-15-5
    - CHEMICAL ABSTRACTS, Database accession no. 97859-49-9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.